With a positive phase 3 trial in hand, Japan’s Daiichi Sankyo plans to file its essential hypertension therapy esaxerenone in its home market.

A new test quickly shows if an antibiotic fights a given infection, which can reduce improperly prescribed antibiotics.

J&J is now assessing what it will take to quell the FDA’s concerns about the safety of the IL-6 monoclonal antibody before deciding on a path forward.

In a first for the Big Pharma and as part of a new model, Pfizer is taking drugs from its shelves and licensing them to its startup, SpringWorks.

Versartis’ somavaratan has failed to match Pfizer’s Genotropin in phase 3, wiping more than 80% off its stock price.

Nestlé is beating a retreat from topical dermatology drug R&D at the cost of up to 450 jobs and possibly a facility.

Andrew Witty jumped into biotech venture capital, Aerie poached another exec from Alcon, Roivant tapped Silicon Valley vet to run trial AI company.

In this week's EuroBiotech Report, phase 3 data send Bavarian Nordic and Nabriva in opposite directions, Immunocore raises $40 million and more. 

In our EuroBiotech roundup this week, Autolus advances CAR-T trial, Cell Medica names CSO and AB Science suffers a regulatory setback.